Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
COVID-19 Vaccine Booster Responses in Patients with Hematologic Malignancies
Patients with hematologic malignancies have varying degrees of immunodeficiency related to the underlying disease and to anti-cancer therapy, with well-documented impairment of COVID-19 vaccine responses and an increased risk for severe or fatal COVID-19 infection. Investigators in the Netherlands assessed humoral anti-spike glycoprotein (S1) and nucleoprotein responses to a third dose of the COVID-19 mRNA-1273 (Moderna) vaccine in patients with hematologic malignancy. The third dose was given 5 months after completion of the standard two-dose schedule.
Both SARS-CoV-2 antibody response and neutralizing capacity against the wild type and variant COVID-19 strains were determined and compared with responses in a cohort of randomly selected, age-matched healthy controls. Patients and controls with a history of COVID-19 infection were excluded.
The analysis included 584 patients with lymphoid, myeloid, and plasma cell neoplasms, some of whom had recently received autologous or allogeneic hematopoietic cell transplantation or CAR-T-cell therapy, and 44 controls. The third vaccine dose was associated with a significant increase in anti-S1-IgG levels — comparable to that in controls — among all disease and therapy subsets except patients with B-cell lymphoma receiving an anti-CD20 monoclonal antibody or CAR T-cell therapy and those with chronic lymphocytic leukemia taking the Bruton tyrosine kinase inhibitor ibrutinib. Neutralizing antibody capacity against COVID variants improved among patients with S1 responses.
These results support booster mRNA COVID-19 vaccination in patients with hematologic malignancies. The study did not assess T-cell response, which may be preserved and may contribute to mitigation of severe infection. The heterogeneity of these cancers and therapies requires individual consideration for vaccination as well as pre- and postexposure prophylaxis. These issues are reviewed in a paper by El Chaer and colleagues (Blood 2022; 140:673).
Haggenburg S et al.
Title: Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19
Source: JAMA Oncol 2022 Aug 11; [e-pub]. (Abstract/FREE Full Text)